Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more
Athira Pharma Inc (ATHA) - Total Assets
Latest total assets as of September 2025: $30.03 Million USD
Based on the latest financial reports, Athira Pharma Inc (ATHA) holds total assets worth $30.03 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Athira Pharma Inc - Total Assets Trend (2018–2024)
This chart illustrates how Athira Pharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Athira Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Athira Pharma Inc's total assets of $30.03 Million consist of 93.3% current assets and 6.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Athira Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Athira Pharma Inc's current assets represent 93.3% of total assets in 2024, a decrease from 99.3% in 2018.
- Cash Position: Cash and equivalents constituted 82.4% of total assets in 2024, up from 67.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Athira Pharma Inc Competitors by Total Assets
Key competitors of Athira Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Athira Pharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Athira Pharma Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Athira Pharma Inc is currently not profitable relative to its asset base.
Athira Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.70 | 2.95 | 43.66 |
| Quick Ratio | 9.70 | 2.95 | 43.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $24.24 Million | $ 54.25 Million | $ 187.93 Million |
Athira Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Athira Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.56 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -63.3% |
| Total Assets | $58.78 Million |
| Market Capitalization | $7.52 Million USD |
Valuation Analysis
Below Book Valuation: The market values Athira Pharma Inc's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Athira Pharma Inc's assets decreased by 63.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Athira Pharma Inc (2018–2024)
The table below shows the annual total assets of Athira Pharma Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $58.78 Million | -63.32% |
| 2023-12-31 | $160.25 Million | -37.93% |
| 2022-12-31 | $258.15 Million | -22.24% |
| 2021-12-31 | $332.01 Million | +18.76% |
| 2020-12-31 | $279.56 Million | +12671.27% |
| 2019-12-31 | $2.19 Million | -55.63% |
| 2018-12-31 | $4.93 Million | -- |